Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
D. van der Heijde¹, Y. Tanaka², Roy Fleischmann³, Edward Keystone⁴, Joel M. Kremer⁵, C. Zerbini⁶, M. H. Cardiel⁷, S. B. Cohen⁸, P. T. Nash⁹, Y. Song¹⁰, D. Tegzova¹¹, B. Wyman¹², D. Gruben¹², B. Benda¹³, G. Wallenstein¹⁴, S. Krishnaswami¹², S. H. Zwillich¹², J. Bradley¹⁵, C. A. Connell¹⁶ and ORAL Scan Investigators¹⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵The Center for Rheumatology, Albany Medical College, Albany, NY, ⁶CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, ⁷Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁸Metroplex Clinical Research Centre, Dallas, TX, ⁹Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Pfizer Inc., Groton, CT, ¹³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ¹⁴Pfizer Inc, New York, NY, ¹⁵Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ¹⁶Pfizer Inc, Groton, CT, ¹⁷Groton
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
Abstract Number: 474 • 2012 ACR/ARHP Annual Meeting
Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses
Mohammed I. Sharif¹, Sudipto Das², Paul Emery³, Helen MacIver¹, Wendy Shingler¹, Philip S. Helliwell⁴, Katharina Sokoll¹ and Edward M. Vital⁵, ¹Rheumatology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom, ²Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Section of Musculoskeletal Disease, NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: The best long-term treatment strategy for rituximab has not been established. Retreatment at a fixed interval of 6 months maintains stable disease activity1 and…
Abstract Number: 327 • 2012 ACR/ARHP Annual Meeting
Tolerogenic Dendritic Cells Ameliorates the Disease Severity of Murine Collagen-Induced Arthritis
Bin Ning¹, Shang-You Yang², Jianlu Wei¹, Weiming Gong¹ and Paul H. Wooley², ¹Orthopaedic Surgery, Shandong University Jinan Central Hospital, Jinan, China, ²Orthopaedic Research Institute, Via Christi Wichita Hospitals, Wichita, KS
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by synovial inflammation, cartilage breakdown and bone destruction with the involvement of various types of…
Abstract Number: 2076 • 2012 ACR/ARHP Annual Meeting
Efficacy of the Potent PI3K-δ,γ Inhibitor IPI-145 in Rat Adjuvant Arthritis
David L. Boyle¹, Katharyn Topoleweski¹ and Gary S. Firestein², ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Phosphoinositide 3-kinase (PI3K) is a family of intracellular signaling transducers and could be targeted to treat inflammatory diseases like rheumatoid arthritis (RA). However, blockade…
Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Mathieu Verdet¹, Clément Guillou², Marie-Laure Potier², Martine Hiron², Fabienne Jouen³, Olivier Boyer⁴, Thierry Lequerré⁵ and Olivier Vittecoq⁶, ¹Rheumatology, Rouen University Hospital, Bois Guillaume, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Immunology, Rouen University Hospital, Rouen Cedex, France, ⁴Immunology, INSERM U905, University of Rouen, Rouen, France, ⁵Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Miho Suzuki¹, Hiroto Yoshida², Misato Hashizume¹, Masashi Shiina², Keisuke Tanaka¹ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Jurgen Wollenhaupt¹, Joel C. Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Koshika Soma⁵, Lisy Wang⁴, Hiroyuki Nakamura⁶, Yoshihiro Komuro⁶, Chudi I. Nduaka⁴, David Gruben⁴, Birgitta Benda⁷, Samuel H. Zwillich⁵, Richard Riese⁴ and John D. Bradley⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Japan Inc., Tokyo, Japan, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Graeme Jones¹, Anthony Sebba², Denise Lepley³, Jenny Devenport⁴, Corrado Bernasconi⁵, Devi Smart⁶, Chiedzo Mpofu⁷ and Juan J. Gomez-Reino⁸, ¹Musculoskeletal, Menzies Research Institute Tasmania, Hobart, Australia, ²University of South Florida, Tampa, FL, ³Medical Affairs Immunology, Genentech, South San Francisco, CA, ⁴Genentech, South San Francisco, CA, ⁵Consultant, Basel, Switzerland, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Roche, Basel, Switzerland, ⁸Rheumatology, Hospital Clinico Universitario, Santiago, Spain
Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1 was the first trial to demonstrate…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 1284 • 2012 ACR/ARHP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
K. L. Winthrop¹, A. Racewicz², E. B. Lee³, B. Wilkinson⁴, S. H. Zwillich⁵, K. Soma⁴, S. Rottinghaus⁴, T. Kawabata⁴, R. Riese⁵, S. Wood⁵, J. Bradley⁶ and Clifton O. Bingham III⁷, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Department of Internal Medicine and Osteoarthrology, Bialystok Regional Hospital, Bialystok, Poland, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁷Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Clinical guidelines recommend the use…
Abstract Number: 463 • 2012 ACR/ARHP Annual Meeting
Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
Helena Forsblad-d'Elia¹, Karin Bengtsson¹, Lars-Erik Kristensen² and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: To evaluate drug survival, clinical response and predictors for drug survival for tocilizumab in patients with rheumatoid arthritis (RA) with inadequate response and/or adverse…
Abstract Number: 1947 • 2012 ACR/ARHP Annual Meeting
Muscle Wasting in HTNFtg Mice, an Animal Model for Rheumatoid Arthritis, Due to Increased Cathepsin L and LC3B Expression
Martin Willburger¹, Birgit Niederreiter¹, Ewald Unger², Josef S. Smolen³, Kurt Redlich¹ and Silvia Hayer¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Center for Medical Physics and Biomedicla Engineering, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: To investigate the impact of systemic inflammation on skeletal muscles in human tumor necrosis factor transgenic (hTNFtg) animals. Methods: We isolated triceps surae, quadriceps,…
Abstract Number: 1294 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis
Melvin A. Churchill¹, Luis F. Flores-Suarez², Daniel J. Wallace³, Kristine Phillips⁴, Richard W. Martin⁵, Mario H. Cardiel⁶, Jeffrey Kaine⁷, Edgar Bautista⁸, David H. Salinger⁹, Erin Stevens⁹, Christopher B. Russell⁹ and David A. Martin⁹, ¹Arthritis Center of Nebraska, Lincoln, NE, ²Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ⁶Research Unit, Hospital, Morelia, Mexico, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Medical Sciences, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA). Brodalumab is…
Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Cesar Vargas-Serafin¹, Luis Aguilar-Lozano¹, Jorge Padilla-Ibarra¹, Carlos Sandoval-Castro¹, Jose Dionisio Castillo-Ortiz¹, Jorge Morales-Torres², Claudia Hernandez² and Cesar Ramos-Remus¹, ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Rheumatology, Hospital Aranda de la Parra, Leon, Mexico
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].